Results 91 to 100 of about 26,068 (276)

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki, Tetsu Watanabe, Mari Shimizu, Shingo Tachibana, Junya Sato, Yuta Kobayashi, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe   +11 more
wiley   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Physiological monitoring in the complex multimorbid heart failure patient - Conclusions. [PDF]

, 2019
Comorbidities are increasingly recognized as crucial components of the heart failure syndrome. Main specific challenges are polypharmacy, poor adherence to treatments, psychological aspects, and the need of monitoring after discharge.
Böhm, M, Coats, AJS, Kindermann, I, Rosano, G, Spoletini, I   +4 more
core   +1 more source

Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion [PDF]

European Heart Journal, 2009
Pre-treatment with mineralocorticoid receptor (MR) antagonists is reported to reduce myocardial infarct size from ischaemia/reperfusion. Here, we tested whether the MR antagonists potassium canrenoate and eplerenone could protect in the more clinically relevant schedule of administration at the end of ischaemia.In all models, hearts were subjected to ...
Katharina, Schmidt, Renaud, Tissier, Bijan, Ghaleh, Tim, Drogies, Stephan B, Felix, Thomas, Krieg   +5 more
openaire   +2 more sources

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection

Медицинский совет, 2018
The article presents the contemporary views of the role of aldosterone in the progression of cardiovascular and renal diseases. It addresses matters related to the efficacy and safety of mineralocorticoid receptor antagonists in patients with chronic ...
A. M. Esayan, A. N. Nimgirova
doaj   +1 more source

Nuclear receptors in vascular biology [PDF]

, 2015
Nuclear receptors sense a wide range of steroids and hormones (estrogens, progesterone, androgens, glucocorticoid, and mineralocorticoid), vitamins (A and D), lipid metabolites, carbohydrates, and xenobiotics.
A Chawla, A McCurley, AA Hamers, AL Bookout, B Fisslthaler, BG Hoebel, C McCarthy, C Zhou, CH Lee, CK Glass, CK Huang, CT Lee, D Bishop-Bailey, D Bishop-Bailey, David Bishop-Bailey, DP Edwards, E Gerlach, F Akbiyik, FA Pereira, FL Wynne, FY Ali, G Pascual, I Dussault, I Spoletini, J He, J Qin, J Sonoda, J Xiang, K Spruiell, KE Swales, L Calza, L Li, L Piqueras, LA Moraes, LA Moraes, LJ Jonk, LR You, M Kaushik, M Matic, N Albermann, N Schafer, N Takamoto, Q Qin, R Zhao, S Asgary, S Chakrabarti, S Marino De, S Stein, SA Kliewer, V Zoete, W El-Sankary, WC Lau, X Wang, Y Ma, Y Sui, Y Sui, YW Hu   +56 more
core   +3 more sources

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Renal function, electrolytes, and congestion monitoring in heart failure. [PDF]

, 2019
Congestion, renal function, and electrolyte imbalance (particularly potassium) are common problems in the management of the complex multi-morbid patient with heart failure (HF).
Chioncel, O, Coats, AJ, Rosano, G, Rossignol, P, Spoletini, I   +4 more
core   +3 more sources